Koki Shimizu

Koki Shimizu

Auto-generated profile, based on publicly available information

Koki Shimizu

Inequalities in Cancer Outcomes Network, Department of Health Services Research and Policy, Faculty of Public Health and Policy London School of Hygiene and Tropical Medicine London UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
YNYoshihiro Nishida
Yoshihiro Nishida
SHShunsuke Hamada
Shunsuke Hamada
AKAkira Kawai
Akira Kawai
TKToshiyuki Kunisada
Toshiyuki Kunisada
AOAkira Ogose
Akira Ogose
HKHiroshi Koike
Hiroshi Koike
This study was undertaken to clarify the risk factors, including the mutation status of CTNNB1 , for the local recurrence after surgery of the rare disease desmoid‐type fibromatosis. It was designed as a multiinstitutional joint research project with 7 major centers in Japan participating. The committee members of 7 major medical centers specializing in bone and soft tissue tumors formed this study group to develop clinical care guidelines. Of 196 cases with specimens and medical records collected from the 7 institutions, 88 surgically treated ones were analyzed regarding clinicopathologic prognostic factors including CTNNB1 mutation status. Excluding R2 cases (n = 3), 5‐year local recurrence‐free survival (LRFS) was 52.9%. No case had received pre‐ or postoperative radiotherapy. Univariate analysis revealed that extremity location (P < .001) and larger size (8 cm or more, P = .036) were significant adverse risk factors for LRFS. Multivariate analysis indicated that extremity location (P < .001) was a significantly adverse factor in addition to recurrent tumor (P = .041), S45F mutation (P = .028), and R1 surgical margin (P = .039). Preoperative drug treatment, including nonsteroidal antiinflammatory drugs, did not reduce the incidence of local recurrence (P = .199). This is the first study to analyze the factors correlating with outcomes of surgical treatment, including CTNNB1 mutation status, in a relatively large number of cases from an Asian country. Tumor location was found to be the most influential prognostic factor for local recurrence, similar to the results from Europe and North America. The development of more sensitive method(s) for determination of CTNNB1 mutation is a priority for future study.

13 April 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KSKoki Shimizu
Koki Shimizu
HMHaruka Maeda
Haruka Maeda
ESEiichiro Sando
Eiichiro Sando
AFAyumi Fujita
Ayumi Fujita
MTMasato Tashiro
Masato Tashiro
KMKonosuke Morimoto
Konosuke Morimoto

14 July 2026 in British Journal of Haematology
Verified
Journal Article
Open access
KSKoki Shimizu
Koki Shimizu
MSMari Kajiwara Saito
Mari Kajiwara Saito
CMCamille Maringe
Camille Maringe
YMYasushi Miyazaki
Yasushi Miyazaki
BRBernard Rachet
Bernard Rachet
Summary: The socioeconomic inequality in acute myeloid leukaemia (AML) survival may be driven by differential access to intensive chemotherapy (ICT). We aimed to quantify socioeconomic inequality in the receipt of ICT among patients with AML in England and identify its key drivers. We evaluated 10 495 patients with de novo AML identified in the national cancer registry of England (2015–2022) along with their area‐deprivation status, as a measure of socioeconomic inequality, and treatment information based on linkage databases. We related prevalence of the ICT receipt to deprivation with multivariable‐adjusted generalised regression and mixed‐effects probit regression. Overall, 5190 patients (49%) received ICT. The patients in the most deprived area were 6.1% less likely to receive ICT than those in the least deprived area. The differences in the prevalence measures varied across the 125 administrative clusters of health service units. If all patients had access to ICT similar to the least deprived patients, 247 more patients would receive ICT. Of the deprivation effect, 94% was estimated to be attributable to the variability among administrative clusters. Despite universal healthcare coverage, socioeconomic inequality exists in AML treatment in England. The inequality may be driven by cluster‐level variations such as institutional culture and resource capacity.